Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967080110> ?p ?o ?g. }
- W2967080110 endingPage "29" @default.
- W2967080110 startingPage "16" @default.
- W2967080110 abstract "Abstract Sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) have been shown to mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 diabetes (T2D) and CV risk factors or CV disease (CVD). In CV outcomes trials (CVOTs) of patients with T2D and established CVD or multiple CV risk factors, empagliflozin and canagliflozin were associated with significant reductions in the risks of major adverse CV events (MACE), hospitalization for heart failure (HF) and kidney disease progression. In the DECLARE–TIMI 58 study, in which the majority of patients did not have established CVD, dapagliflozin was associated with significant reductions in the composite end point of CV death or hospitalization for HF and was noninferior to placebo with regard to MACE; although patients had relatively good renal function, dapagliflozin also showed renal benefits similar to those seen with empagliflozin and canagliflozin. This article reviews the increased risk of CVD and renal disease in patients with T2D and discusses the potential mechanisms of the cardioprotective and renoprotective effects of SGLT‐2i therapy. The observed improvements in CV and renal outcomes with SGLT‐2is in CVOTs suggest a class effect in this patient population and have influenced treatment guidelines for the way add‐on therapy to metformin is initiated in patients with T2D and high CV risk. The overall cardioprotective and renoprotective effects of SGLT‐2is in patients with T2D and high CV risk are most likely attributable to multiple mechanisms, including cardiac, haemodynamic, metabolic, anti‐inflammatory and renal effects." @default.
- W2967080110 created "2019-08-22" @default.
- W2967080110 creator A5083786375 @default.
- W2967080110 date "2019-08-30" @default.
- W2967080110 modified "2023-09-30" @default.
- W2967080110 title "Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes" @default.
- W2967080110 cites W1503352903 @default.
- W2967080110 cites W1511683349 @default.
- W2967080110 cites W1584301804 @default.
- W2967080110 cites W1773086197 @default.
- W2967080110 cites W1887831497 @default.
- W2967080110 cites W1957004156 @default.
- W2967080110 cites W1978493049 @default.
- W2967080110 cites W1986276307 @default.
- W2967080110 cites W1990025047 @default.
- W2967080110 cites W1996837305 @default.
- W2967080110 cites W2000262648 @default.
- W2967080110 cites W2001045885 @default.
- W2967080110 cites W2039104561 @default.
- W2967080110 cites W2042291132 @default.
- W2967080110 cites W2078330387 @default.
- W2967080110 cites W2095521683 @default.
- W2967080110 cites W2099484221 @default.
- W2967080110 cites W2105731956 @default.
- W2967080110 cites W2107146663 @default.
- W2967080110 cites W2118613762 @default.
- W2967080110 cites W2120922908 @default.
- W2967080110 cites W2122077393 @default.
- W2967080110 cites W2123786774 @default.
- W2967080110 cites W2124658554 @default.
- W2967080110 cites W2134304394 @default.
- W2967080110 cites W2135302420 @default.
- W2967080110 cites W2139339820 @default.
- W2967080110 cites W2146264128 @default.
- W2967080110 cites W2153839551 @default.
- W2967080110 cites W2153957843 @default.
- W2967080110 cites W2155287847 @default.
- W2967080110 cites W2157405334 @default.
- W2967080110 cites W2162078466 @default.
- W2967080110 cites W2167984652 @default.
- W2967080110 cites W2196646992 @default.
- W2967080110 cites W2253712555 @default.
- W2967080110 cites W2257723432 @default.
- W2967080110 cites W2297835124 @default.
- W2967080110 cites W2341643234 @default.
- W2967080110 cites W2412800896 @default.
- W2967080110 cites W2412895812 @default.
- W2967080110 cites W2416348735 @default.
- W2967080110 cites W2424539745 @default.
- W2967080110 cites W2492672367 @default.
- W2967080110 cites W2512006388 @default.
- W2967080110 cites W2513473588 @default.
- W2967080110 cites W2515456868 @default.
- W2967080110 cites W2526854609 @default.
- W2967080110 cites W2532735232 @default.
- W2967080110 cites W2550194700 @default.
- W2967080110 cites W2553261268 @default.
- W2967080110 cites W2557156634 @default.
- W2967080110 cites W2562563466 @default.
- W2967080110 cites W2576291926 @default.
- W2967080110 cites W2582603147 @default.
- W2967080110 cites W2591585197 @default.
- W2967080110 cites W2607460565 @default.
- W2967080110 cites W2614137535 @default.
- W2967080110 cites W2614165776 @default.
- W2967080110 cites W2617488317 @default.
- W2967080110 cites W2618738897 @default.
- W2967080110 cites W2618771417 @default.
- W2967080110 cites W2620245977 @default.
- W2967080110 cites W2624032915 @default.
- W2967080110 cites W2626446274 @default.
- W2967080110 cites W2679905442 @default.
- W2967080110 cites W2745253866 @default.
- W2967080110 cites W2756910166 @default.
- W2967080110 cites W2765097799 @default.
- W2967080110 cites W2768451744 @default.
- W2967080110 cites W2768576350 @default.
- W2967080110 cites W2774805246 @default.
- W2967080110 cites W2782992901 @default.
- W2967080110 cites W2784171922 @default.
- W2967080110 cites W2791830621 @default.
- W2967080110 cites W2792576512 @default.
- W2967080110 cites W2793906475 @default.
- W2967080110 cites W2798146738 @default.
- W2967080110 cites W2800277129 @default.
- W2967080110 cites W2806818105 @default.
- W2967080110 cites W2807239802 @default.
- W2967080110 cites W2808467887 @default.
- W2967080110 cites W2808915250 @default.
- W2967080110 cites W2809440745 @default.
- W2967080110 cites W2833091206 @default.
- W2967080110 cites W2883419804 @default.
- W2967080110 cites W2884466498 @default.
- W2967080110 cites W2890282628 @default.
- W2967080110 cites W2890465901 @default.
- W2967080110 cites W2890539106 @default.
- W2967080110 cites W2892498615 @default.
- W2967080110 cites W2894993577 @default.